The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Value Outlook For The Phesgo Market Through 2030?
Historic growth stemmed from a rising detection of HER2-positive breast cancer, advancements in the development of monoclonal antibodies, the expansion of oncology infusion centers, improved patient survival outcomes with targeted therapy, and an increase in biologic drug approvals.
The anticipated growth during the forecast period is propelled by the broadening of oncology treatment approaches in home settings, increased funding directed towards combined biologic therapies, the wider embrace of medication delivery via subcutaneous routes, progress in technologies that enhance formulation stability, and an escalating need for highly effective cancer therapy guidelines.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20347&type=smp
Which Growth Factors Are Strengthening The Phesgo Market Landscape?
The rising occurrence of breast cancer is anticipated to drive the expansion of the phesgo market in the future. This condition, breast cancer, originates in mammary cells, often within milk ducts or lobules, and possesses the capability to metastasize throughout the body. Its growing prevalence is linked to various elements including an aging demographic, inherited genetic susceptibilities, evolving lifestyles, environmental contaminants, and hormonal factors. Phesgo offers support to individuals with breast cancer by providing a user-friendly, pre-set dose blend of pertuzumab and trastuzumab. These two targeted treatments act together to suppress the HER2 protein, which is key for tumor development and spread, simultaneously cutting down on treatment duration and enhancing the patient’s entire treatment journey. For example, data from the American Cancer Society, a professional body based in the US, indicates that new breast cancer diagnoses in the United States increased from 300,590 in 2023 to 313,510 in 2024. Consequently, the expanding occurrence of breast cancer is fueling the growth of the phesgo market. The increasing need for individualized medicine is projected to stimulate the expansion of the phesgo market moving ahead. Individualized medicine involves customizing medical care to match each patient’s unique attributes, such as their genetic profile, way of life, and surroundings, thereby delivering more potent and specific treatments. This rising demand for personalized approaches stems from progress in genomics, which facilitates customized therapies that enhance patient results and minimize adverse reactions. Phesgo contributes to personalized medicine by merging pertuzumab and trastuzumab, specific therapies designed to inhibit the HER2 protein in patients with HER2-positive breast cancer, into a singular subcutaneous injection. This method simplifies treatment administration and corresponds with the precise care requirements of individual patients. For example, in February 2024, the Personalized Medicine Coalition, a non-profit organization located in the US, reported that in 2023, the FDA sanctioned 16 novel personalized treatments for individuals suffering from rare diseases, an increase from six approvals in 2022. Among the personalized treatments newly approved in 2023 were also seven medications for cancer and three for various other illnesses and health conditions. Consequently, the escalating need for personalized medicine is propelling the expansion of the phesgo market.
What Are The Major Segment Categories Within The Phesgo Market?
The phesgo market covered in this report is segmented –
1) By Indication: Early Breast Cancer, Metastatic Breast Cancer
2) By Formulation: Subcutaneous Injection, Intravenous Infusion
3) By Distribution Channel: Direct Sales, Online Pharmacies, Wholesale Distributors
4) By End User: Hospitals, Oncology Clinics, Home Healthcare
What Trends Are Influencing The Future Of The Phesgo Market?
Leading companies active in the phesgo market are concentrating on introducing innovative therapies, such as monoclonal antibody combination therapy, to enhance the effectiveness of treatment and improve patient outcomes in oncology. Monoclonal antibody combination therapy involves the simultaneous use of two or more monoclonal antibodies to target distinct aspects of a disease, often leading to improved treatment efficacy and overcoming potential resistance mechanisms. For example, in November 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, released Phesgo combination for Subcutaneous Injection MA, IN. Phesgo is an injectable medication that combines pertuzumab and trastuzumab, which are two monoclonal antibodies, with hyaluronidase alfa, for the treatment of HER2-positive breast cancer and advanced HER2-positive colorectal cancer, providing a convenient subcutaneous administration option as an alternative to intravenous infusion.
Who Are The Businesses Driving Activity In The Phesgo Market?
Major companies operating in the phesgo market are F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co. Ltd.
Access The Complete Phesgo Market Report:
https://www.thebusinessresearchcompany.com/report/phesgo-global-market-report
Which Region Leads The Phesgo Market By Size?
North America was the largest region in the phesgo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phesgo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model